Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Antonia, S. J.; Brahmer, J. R.; Khleif, S.; Balmanoukian, A. S.; Ou, S. H. I.; Gutierrez, M.; Kim, D. W.; Kim, S. W.; Ahn, M. J.; Leach, J.; Jamal, R.; Jaeger, D.; Jerusalem, G.; Jin, X.; Gupta, A.; Antal, J.; Segal, N. H. |
| Abstract Title: | Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC) |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi421 |
| Language: | English |
| ACCESSION: | WOS:000393913000308 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdw383.16 |
| Notes: | Meeting Abstract: 1216PD -- Source: Wos |
